JP2011515349A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515349A5
JP2011515349A5 JP2010550897A JP2010550897A JP2011515349A5 JP 2011515349 A5 JP2011515349 A5 JP 2011515349A5 JP 2010550897 A JP2010550897 A JP 2010550897A JP 2010550897 A JP2010550897 A JP 2010550897A JP 2011515349 A5 JP2011515349 A5 JP 2011515349A5
Authority
JP
Japan
Prior art keywords
uric acid
pharmaceutical composition
composition according
dimethylbenzyloxy
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010550897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515349A (ja
JP5339545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/037128 external-priority patent/WO2009151695A1/en
Publication of JP2011515349A publication Critical patent/JP2011515349A/ja
Publication of JP2011515349A5 publication Critical patent/JP2011515349A5/ja
Application granted granted Critical
Publication of JP5339545B2 publication Critical patent/JP5339545B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010550897A 2008-03-13 2009-03-13 尿酸を減少させる化合物及び方法 Expired - Fee Related JP5339545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3629408P 2008-03-13 2008-03-13
US61/036,294 2008-03-13
PCT/US2009/037128 WO2009151695A1 (en) 2008-03-13 2009-03-13 Compounds and method for reducing uric acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012035313A Division JP5547222B2 (ja) 2008-03-13 2012-02-21 尿酸を減少させる化合物及び方法

Publications (3)

Publication Number Publication Date
JP2011515349A JP2011515349A (ja) 2011-05-19
JP2011515349A5 true JP2011515349A5 (https=) 2012-04-12
JP5339545B2 JP5339545B2 (ja) 2013-11-13

Family

ID=41417026

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010550897A Expired - Fee Related JP5339545B2 (ja) 2008-03-13 2009-03-13 尿酸を減少させる化合物及び方法
JP2012035313A Expired - Fee Related JP5547222B2 (ja) 2008-03-13 2012-02-21 尿酸を減少させる化合物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012035313A Expired - Fee Related JP5547222B2 (ja) 2008-03-13 2012-02-21 尿酸を減少させる化合物及び方法

Country Status (17)

Country Link
US (2) US8829058B2 (https=)
EP (2) EP3517109A1 (https=)
JP (2) JP5339545B2 (https=)
KR (2) KR101677945B1 (https=)
CN (2) CN102976928B (https=)
AU (1) AU2009258040B8 (https=)
BR (2) BRPI0909299B1 (https=)
CA (1) CA2716860C (https=)
DK (1) DK2268141T3 (https=)
ES (1) ES2741153T3 (https=)
IL (2) IL208004A (https=)
MX (2) MX2010009959A (https=)
NZ (2) NZ587433A (https=)
RU (2) RU2501554C2 (https=)
UA (2) UA103894C2 (https=)
WO (1) WO2009151695A1 (https=)
ZA (1) ZA201005872B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5339545B2 (ja) 2008-03-13 2013-11-13 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる化合物及び方法
MX2010011603A (es) 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.
WO2011046800A1 (en) * 2009-10-13 2011-04-21 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
WO2012033720A1 (en) 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
WO2012102405A1 (ja) 2011-01-28 2012-08-02 佐藤製薬株式会社 縮環化合物
WO2012125533A1 (en) * 2011-03-14 2012-09-20 Wellstat Therapeutics Corporation 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
CN104602686A (zh) * 2012-04-13 2015-05-06 西玛贝医药公司 利用卤芬酯或卤芬酸以及抗炎剂治疗痛风患者中高尿酸血症的方法
CA3128846C (en) 2012-07-27 2025-05-06 Sato Pharmaceutical Co. Ltd. COMPOSITE OF DIFLUOROMETHYLENE
US11000492B2 (en) 2015-11-13 2021-05-11 The Trustees Of Columbia University In The City Of New York Fluorenone compound for the treatment of gout
US12057228B1 (en) 2015-12-30 2024-08-06 Cerner Innovation, Inc. Predicting newly incident chronic kidney disease
CN106190954B (zh) * 2016-07-25 2019-12-10 华南理工大学 一种高尿酸血症肝细胞模型及其构建方法
CN106190953B (zh) * 2016-07-25 2019-12-10 华南理工大学 一种高尿酸血症细胞模型及其构建方法与在降尿酸功效评价方面的应用
KR101988867B1 (ko) 2017-07-25 2019-06-13 광주과학기술원 금 나노입자를 이용한 요산 분해용 조성물
WO2019066469A1 (ko) * 2017-09-27 2019-04-04 경북대학교 산학협력단 페북소스타트 또는 토피록소스타트의 암 전이의 예방 및 치료제로서의 용도
WO2021194294A1 (ko) * 2020-03-27 2021-09-30 가톨릭대학교 산학협력단 자가면역질환 평가 아바타 모델 플랫폼
KR102836208B1 (ko) * 2020-03-27 2025-07-18 가톨릭대학교 산학협력단 통풍 동반 관절염 모델 평가 플랫폼

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572512B1 (fr) 1984-10-25 1987-09-25 Luchaire Sa Dispositif, adaptable sur engins ou munitions, tels que projectiles d'artillerie, destine a reduire leur trainee de culot
DE3884825D1 (de) 1987-02-16 1993-11-18 Konishiroku Photo Ind Entwickler für lichtempfindliche lithographische Druckplatte, gemeinschaftlich verarbeitungsfähig für den Negativ-Typ und den Positiv-Typ und Entwicklerzusammensetzung für lichtempfindliches Material.
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
AU4953796A (en) 1995-03-15 1996-10-02 Sanyko Company, Limited Dipeptide compounds having ahpba structure
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CA2502297C (en) 2002-11-01 2011-12-13 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
MXPA05008600A (es) 2003-02-13 2005-11-04 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
CN1774244A (zh) 2003-04-15 2006-05-17 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
MXPA05011592A (es) 2003-04-30 2005-12-15 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
TWI280136B (en) * 2003-05-30 2007-05-01 Lytone Enterprise Inc Composition containing dipeptide of histidine and alanine for reducing uric acid
AU2005247473A1 (en) 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
US7622491B2 (en) 2004-08-13 2009-11-24 Metabolex Inc. Modulators of PPAR and methods of their preparation
US7494537B2 (en) 2004-11-15 2009-02-24 The Pilot Ink Co., Ltd. Thermochromic coloring color-memory composition and thermochromic coloring color-memory microcapsule pigment containing the same
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
UA95613C2 (ru) 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
NZ569729A (en) 2006-01-25 2011-07-29 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
US20070197512A1 (en) 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
KR20080106455A (ko) * 2006-03-31 2008-12-05 웰스태트 테러퓨틱스 코포레이션 대사장애의 조합치료
JP5252585B2 (ja) * 2006-06-09 2013-07-31 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
WO2008022267A2 (en) * 2006-08-17 2008-02-21 Wellstat Therapeutics Corporation Combination treatment for metabolic disorders
JP5496913B2 (ja) 2008-01-15 2014-05-21 ウェルスタット セラピューティクス コーポレイション 代謝異常の治療のための化合物
JP5339545B2 (ja) 2008-03-13 2013-11-13 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる化合物及び方法
MX2010011603A (es) 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.
WO2012033720A1 (en) 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid

Similar Documents

Publication Publication Date Title
JP2011515349A5 (https=)
JP2011519865A5 (https=)
KR101567885B1 (ko) 고요산혈증 및 고요산혈증 관련 대사 장애를 치료하기 위한 방법 및 조성물
RU2012110592A (ru) Соединения и способ снижения мочевой кислоты
US20040023840A1 (en) Combination of organic compounds
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
JP2010518122A5 (https=)
RU2010148762A (ru) Тетразольные соединения для снижения концентрации мочевой кислоты
JP2016164165A5 (https=)
ES2449340T3 (es) Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales
JP2013510169A5 (https=)
AU2020201980A1 (en) Combination of FXR agonists
JP2014532758A5 (https=)
JP2013507438A5 (https=)
MX357507B (es) Metodos para tratar hiperucemia en pacientes con gota utilizando halofenato o acido halofenico y un segundo agente de reduccion de urato.
JP5439817B2 (ja) 尿排出障害治療剤
JP7658909B2 (ja) 筋ジストロフィー治療薬
TW201215389A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
ES2779724T3 (es) Prevención y/o agente terapéutico para la fibromialgia
RU2007129567A (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
JP2005519918A5 (https=)
JP2008525314A5 (https=)
JP2006045200A (ja) 間質性膀胱炎の治療薬
NZ614486B2 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
RU2007129568A (ru) Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии